Eosinophils in disease'
There have been several significant developments in knowledge about the constituents and properties of human eosinophils. Many of the eosinophil granule proteins have been isolated and defined, and it has been demonstrated recently that blood eosinophils can be induced to develop an increased cytotoxic capacity. The signals which may induce eosinophils to release their granule proteins are now being defined, and clinical studies on patients with marked eosinophilia have brought to light a number of possible roles for eosinophils in the pathogenesis of disease.
Eosinophil granule proteins: A number of the granule proteins have been purified (Table 1) . ability of eosinophils to secrete ECP in vitro has been measured (Winqvist et al. 1984) . After 40 min incubation with sepharose-C3b, 15% was released. This was inhibited both by hydrocortisone and cytochalasin B. Interestingly, neither concanavalin A-sepharose nor the calcium ionophore A23187 induced ECP release, although they induced neutrophil degranulation. The density of eosinophils was shown to be related to their granularity. The normal density of eosinophils in colloidal silica was 1.090, but in patients with parasitic diseases it was increased, and reduced in patients with immune complex diseases. In patients with eosinophilic leukaemia, blood eosinophil densities were high or low. In patients with the hypereosinophilic syndrome, light-degranulated cells were seen and these had increased 02 consumption and increased Fc receptors for IgG (Winqvist et al. 1982) . These light cells were also seen in eosinophilic pleural exudates. Dr Monique Capron (Lille, France) reported similar findings, and confirmed the heterogeneity of blood eosinophils in these patients using a number of biochemical criteria.
Recent studies on the properties, localization and functions of eosinophil granule major basic protein (MBP) were reviewed by Dr Steven Ackerman (Mayo Clinic, USA). Comparative immunochemical and physicochemical studies of MBP, ECP, and the eosinophil-derived neurotoxin (EDN) demonstrated that these proteins were distinct cationic moieties of the human eosinophil granule (Ackerman et al. 1984) . Measurements of the concentrations of MBP and ECP in acid extracts of eosinophils from patients with-eosinophilia showed that there was 6 to 64 times more MBP than ECP in their granules. EDN has been difficult to separate from ECP, but this has now been achieved by affinity chromatography with heparin-sepharose CL-6B. This should lead to further insights into the relationship between EDN and the closely-related (if not identical) protein, eosinophil protein-X (EP-X). In experimental animals inoculated into the cerebrospinal fluid with these cationic proteins, there was a loss of Purkinje cells and demyelinationthe 'Gordon phenomenon'. However, as yet, there is no evidence that these proteins cause a similar neurological disease in man.
Studies were reported where indirect immunofluorescence had been done with antibodies to see whether MBP could be localized extracellularly in tissue lesions where tissue damage or parasite destruction was seen in association with eosinophil infiltration. Local deposits of extracellular MBP were detected in the skin of 6 patients with onchocerciasis after, but not before, treatment with diethylcarbamazine (Kephart et al. 1983 ). The deposits of MBP were most prominent in areas where extensive eosinophil degranulation had occurred around damaged and degenerating microfilariae. Marked deposition of MBP was also observed in areas of oedema in the skin lesions in 12 out of 28 patients with chronic idiopathic urticaria (Peters et al. 1983 ). Dense deposits of MBP were also seen in the skin of 4 patients with eosinophilic cellulitis (Well's disease), localized to the flame figures and adjacent collagen-rich lesions.
Recent in vitro studies showed that MBP, but not ECP or EDN, stimulated an IgEindependent, noncytolytic, energy and temperature dependent histamine release from human basophils (O'Donnell et al. 1983 ). The kinetics of release were similar to those reported for polycations such as poly-L-arginine. These results support the concept of a bidirectional basophil/mast cell eosinophil regulatory axis, and suggest that MBP may play a significant role in stimulating or potentiating basophil/mast cell mediator release in immediate hypersensitivity reactions.
Dr Po-Chun Tai (Royal Postgraduate Medical School, London) discussed the properties of several mouse monoclonal antibodies that she had raised to eosinophil granule and membrane constituents. Two antibodies were well characterized (Tai et al., in preparation). One antibody to ECP (antibody EG 1) bound to eosinophils from normal individuals and patients. A second antibody (EG 2) also recognized ECP but was specific for the secreted form of the protein, and it also bound to EP-X. This suggested that there were structural alterations in these proteins during secretion, and that ECP and EP-X are homologous, or have common epitopes. They have similar molecular weights and isoelectric points, and are difficult to separate from each other. A particularly interesting property of antibody EG 2 was that it did not bind to blood eosinophils in normal individuals, but was apparently specific for eosinophils which were mobilizing their granules during activation (with eosinophil cytotoxicity enhancing factor) or phagocytosis. It was found that a proportion of blood eosinophils in patients with the hypereosinophilic syndrome bound antibody EG 2. Eosinophil vacuoles were also strongly stained in immunocytochemical studies. This provided further support for the suggestion that these morphologically abnormal cells were secreting their granule constituents in vivo.
There has been great interest in the possibility of producing monoclonal antibodies which are specific for eosinophil plasma membrane antigens. Dr Tai and other groups have developed panels of antimembrane antibodies which bind preferentially to eosinophils, but as yet none has been shown to be specific. Further work is needed to study the possibility that these antibodies detect eosinophil differentiation antigens or stages in maturation. They may also define variations in development which could give rise to eosinophil subpopulations. Eosinophil activation: It has been shown that patients with an eosinophilia may have blood eosinophils with a greater capacity to kill antibody-coated schistosomule larvae (schistosomula) than normal blood eosinophils (David et al. 1980 ). This has led several groups to study the possibility that eosinophils can be activated, in much the same way as macrophages (Table 2) . (Vadas 1983) . Eosinophilopoictic activity was assessed by measuring the nutnber of eosinophilic colonies which grew from mouse marrow cells cultured for two weeks in soft agar. He showed that these factors induced both increased eosinophilopoiesis and an increased capacity for eosinophils to lyse antibody-coated target cells -'activation'. He suggested that this would explain the earlier observation that schistosomule killing by patients' eosinophils was greatest when the cells had been purified from those with the highest blood eosinophil counts (David et al. 1980) . One class of activating factor was obtained from human placental conditioned medium (HPCM) (Vadas et al. 1981 ). The activating factor had all the properties of CSF-a, one of two types of colony stimulating factors (CSF) purified from HPCM. It was also noted that CSF-a had eosinophilopoietic activity, whilst the other inactive CSF (CSF-fI) from HPCM had only granulocyte/macrophage colony stimulating activity (Vadas et al. 1983 ). Both CSFs stimulated neutrophil-mediated, antibody-dependent killing of tumours, suggesting that specific receptors for CSFs exist on granulocytes. CSF-i increased the amount of eosinophil autofluorescence, assessed in a fluorescence-activated cell sorter, possibly due to an increase in the cell content of flavine adenine dinucleotide. It was suggested that this might be a rapid way to measure eosinophil activation in vitro.
Several tumour cell lines of mouse and human origin were found to have the capacity to generate cosinophil-activating and eosinophilopoictic factors in culture. One of these, from the mouse T-cell line EL 4, induced a pure growth of eosinophil colonies from cultured human marrow in soft agar. Another human cell line, 5637, derived from a bladder carcinoma, appeared to produce both eosinophil-activating factor and CSF-ax. These findings may explain how some tumours, especially those of T-cell origin and carcinomas, may be associated with a marked increase in blood eosinophils, many of which appear to be activated. A pancreatic carcinoma cell line, MIA produced an inhibitor of eosinophil killing, and this inhibitory factor could be separated from CSF by column chromatography. The possibility that there are 'downregulators' of eosinophils needs to be studied further.
Dr Anthony Butterworth (Department of Pathology, Cambridge) reviewed the experiments which have demonstrated the existence of an eosinophil-activating factor which increased the capacity of human cosinophils to kill IgG antibody-coated schistosomula (Veith & Butterworth 1983) . This factor was produced by cultured human blood monocytes. It was heat and acid stable, and was trypsin-labile, with a molecular weight of about 25-40 000 daltons. It was of interest that monocytes from patients with an eosinophilia made more activating factor than those from noneosinophilic individuals. The mechanism of increased parasite killing appeared to involve the early temperature-dependent stage of attachment of eosinophils to the parasites. A related, and possibly identical, factor has been found in supernatants from stimulated human lymphocytes and unstimulated monocytes (Dessein et al. 1982) . His group has also found a comparable factor in supernatants from cultures of the human tumour cell lines U 937 and HL 60. Taken together with the work of Vadas and his colleagues, these experiments have shown clearly that eosinophil effector functions are regulated, and therefore subject to considerable variations in different circumstances. This conclusion suggests that there should be a fresh appraisal of the possible roles of eosinophils in different disorders. The results of studies on eosinophils derived from patients with one disease may not necessarily be applicable to another.
Interaction of eosinophils with immunoglobulins:
This area was discussed by Dr Monique Capron (Institut Pasteur, Lille, France). First she described experiments concerning the role of antibody-mediated, eosinophil-dependent effector systems in antischistosome immunity. Rat monoclonal IgG2a and IgE antibodies to the integument of schistosomula not only enabled eosinophils to kill them in vitro, but also protected the rats against schistosome infection. In addition, passive transfer of eosinophils from infected rats to normals also induced a protective effect. The participation of cytophilic antibodies in this protective effect was suggested by experiments in which normal eosinophils were passively sensitized with antibodies (Capron et al. 1 984a).
The finding that IgE antibodies were involved in rat eosinophil-mediated killing (Capron et al. 1981) raised the possibility that human eosinophils might also possess IgE receptors. In an elegant series of experiments she showed that these receptors were present on human eosinophils, and that they were comparable to IgE receptors on lymphocytes and monocytes with a similar antigenicity and low binding affinity (Capron et al. 1984b (Kay 1983, Kay & Walsh, in preparation) . IgG rosettes were enhanced following incubation with various chemotactic factors including leukotriene B4 and f-met-leu-phe. These chemoattractants also enhanced eosinophilmediated, complement-dependent killing of schistosomula, but the effect was only just statistically significant with eosinophils, a greater percentage enhancement being achieved by neutrophils.
Patients with eosinophilia: Studies on the involvement of eosinophils in tissue injury in patients with eosinophilia, especially the idiopathic hypereosinophilic syndrome (HES), was discussed by Dr Christopher Spry (Royal Postgraduate Medical School, London). He reviewed the principal features of HES (Spry 1982), including the most serious complications: endomyocardial disease (Davies et al. 1983 ) and thromboembolic disease, especially when this involved the brain (Spry et al. 1983) . Some experimental evidence supported the suggestion that some or all of these complications were the result of the release of large amounts of eosinophil granule proteins, especially ECP, into the blood and tissues (Tai et al. 1982) . Other work showed that ECP affected the intrinsic coagulation system, and increased the thrombogenic properties of endothelial cells in culture. High serum levels of ECP were found in patients with eosinophilic endomyocardial disease, and activated eosinophils with secreted ECP were also found in areas of acute necrosis in the heart. This provided additional evidence for the possible toxic properties of degranulating eosinophils in tissues.
The main conclusions from this meeting were that eosinophils undergo a series of differentiation steps, which proceed to degranulation and release of the granule proteins which have many biological effects. The ways in which activation and degranulation are regulated are now being discovered, and this should provide new insights into the many interesting properties and roles for eosinophils in parasitic, allergic and other diseases.
